Holiday Deals Start Now! Save 30% on CEFALY DUAL & 10% on Electrodes

2 billion

migraines treated since 2008.

79%

of acute migraine sufferers
saw pain relief[1]

350,000

devices sold.

Cefaly Device Image

The CEFALY DUAL neuromodulator (e-TNS) is the first FDA Cleared and CE Marked medical device of its kind for the treatment of migraine.

CEFALY DUAL is indicated to be used for:

  • Acute treatment of migraine with or without aura in patients 18 years of age or older.
  • Preventative treatment of episodic migraine with in patients 18 years of age or older.

CEFALY is ideal for people with migraine who:

  • Don’t respond to pharmaceutical treatments or seek clinically proven effective alternatives to pharmaceuticals.
  • Have prior medical conditions and are unable to take traditional pharmaceuticals.
  • Have limited access to outpatient treatment procedures.

See Contraindications, Precautions and Warnings.

CEFALY blocks migraine pain and provides relief during attacks

In a double-blind, randomized, sham-controlled study conducted across multiple headache centers in the U.S. patients saw a reduction in migraine pain intensity following a 60-minute ACUTE treatment session with CEFALY.

  • An average 59% reduction in migraine pain intensity following one hour of treatment with CEFALY. This relief continued up to 24 hours.
  • 79% of Acute migraine sufferers saw pain relief.
  • 32% of Acute migraine sufferers saw pain freedom.
  • No adverse events reported
59% reduction in migraine pain intensity with CEFALY
Pain Relief with CEFALY
Total Pain Freedom with CEFALY
Read complete ACUTE Migraine Treatment Study.

Chou D. E. et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019; 39(1): 3-14.

CEFALY significantly reduces number of migraine days

In a double-blind, randomized, sham-controlled study conducted across multiple Belgian tertiary headache centers patients with compliant daily use of CEFALY 20-minute PREVENT treatment experienced a significant reduction in number of migraine days.

  • Mean 2.06 (30%) reduction in migraine days in verum group.
  • 38.1% of CEFALY users saw at least 50% reduction in number of migraine days.
  • Adverse events were mild and fully reversible within 20 minutes, without intervention.
CEFALY significantly reduces number of migraine days
Read complete PREVENT migraine treatment study.

PREMICE STUDY Migraine prevention with a supraorbital transcutaneous stimulator. A randomized controlled trial. Jean Schoenen, Bart Vandersmissen, Sandrine Jeangette, Luc Herroelen, Michel Vandenheede, Pascale Gerard, Delphine Magis. Neurology Feb 2013, 80 (8) 697-704; DOI: 10.1212/WNL.0b013e3182825055

CEFALY DUAL clinical trials have shown side effects to be minor and fully reversible.

Most Common (5% of users)

  • Intolerance
  • Mild Sedative Effect
  • Allergic Contact Dermatitis

Less Common (2-5% of users)

  • Headache
  • Persistent Sensation
  • Neck Muscle Tightness

Rare (<2% of users)

  • Nausea
  • Tinnitus
  • Tooth Pain
  • Hyperlacrimation